Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001711279-26-000021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-02-26 | 2026-02-24+ | KRYS | JANNEY DANIEL | Dir | S - Sale+OE | $271.09 | -22.3K | 92.8K | -19% | -$6.04M |
| DM | 2026-02-26 | 2026-02-24 | KRYS | JANNEY DANIEL | Dir | S - Sale+OE | $266.88 | -37.9K | 743 | -98% | -$10.11M |
| D | 2026-02-26 | 2026-02-24 | KRYS | JANNEY DANIEL | Dir | M - OptEx | $2.46 | +37.9K | 37.9K | New | +$93.2K |
| D | 2026-02-26 | 2026-02-24 | KRYS | JANNEY DANIEL | Dir | M - OptEx | $0.00 | -37.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | S | D | 2,425 | $274.90 | 93,537 | I | — | — | (F20) The transaction was executed in multiple trades ranging from $274.59 to $275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Stock | 2026-02-24 | S | D | 1,674 | $268.67 | 96,892 | I | — | — | (F18) The transaction was executed in multiple trades ranging from $268.0725 to $269.0705. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 3 | Common | Common Stock | 2026-02-24 | S | D | 930 | $269.50 | 95,962 | I | — | — | (F19) The transaction was executed in multiple trades ranging from $269.1641 to $269.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4 | Common | Common Stock | 2026-02-24 | S | D | 1,891 | $267.37 | 98,566 | I | — | — | (F17) The transaction was executed in multiple trades ranging from $267.0631 to $268.0275. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 5 | Common | Common Stock | 2026-02-24 | S | D | 4,339 | $266.62 | 100,457 | I | — | — | (F16) The transaction was executed in multiple trades ranging from $266.06 to $267.0511. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 6 | Common | Common Stock | 2026-02-24 | S | D | 1,604 | $265.54 | 104,796 | I | — | — | (F15) The transaction was executed in multiple trades ranging from $265.04 to $266. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 7 | Common | Common Stock | 2026-02-24 | S | D | 900 | $264.60 | 106,400 | I | — | — | (F14) The transaction was executed in multiple trades ranging from $264.01 to $264.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 8 | Common | Common Stock | 2026-02-24 | S | D | 62 | $263.05 | 107,300 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F12) The transaction was executed in multiple trades ranging from $262.9496 to $263.1269. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 9 | Common | Common Stock | 2026-02-24 | S | D | 373 | $271.09 | 0 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F10) The transaction was executed in multiple trades ranging from $270.650 to $271.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 10 | Common | Common Stock | 2026-02-24 | S | D | 370 | $269.83 | 373 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F9) The transaction was executed in multiple trades ranging from $269.610 to $270.140. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 11 | Common | Common Stock | 2026-02-26 | S | D | 2,638 | $276.32 | 85,096 | I | — | — | (F23) The transaction was executed in multiple trades ranging from $276 to $276.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 12 | Common | Common Stock | 2026-02-26 | S | D | 5,103 | $275.28 | 87,734 | I | — | — | (F22) The transaction was executed in multiple trades ranging from $275 to $275.9782. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 13 | Common | Common Stock | 2026-02-25 | S | D | 700 | $275.00 | 92,837 | I | — | — | (F21) The transaction was executed in a single trade. |
| 14 | Common | Common Stock | 2026-02-24 | M | A | 37,895 | $2.46 | 37,895 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 15 | Common | Common Stock | 2026-02-24 | S | D | 569 | $262.91 | 37,326 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F2) The transaction was executed in multiple trades ranging from $262.480 to $263.400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 16 | Common | Common Stock | 2026-02-24 | S | D | 1,733 | $264.12 | 35,593 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F3) The transaction was executed in multiple trades ranging from $263.510 to $264.450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 17 | Common | Common Stock | 2026-02-24 | S | D | 3,557 | $265.08 | 32,036 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F4) The transaction was executed in multiple trades ranging from $264.520 to $265.495. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 18 | Common | Common Stock | 2026-02-24 | S | D | 8,986 | $266.18 | 23,050 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F5) The transaction was executed in multiple trades ranging from $265.520 to $266.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 19 | Common | Common Stock | 2026-02-24 | S | D | 11,673 | $266.97 | 11,377 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F6) The transaction was executed in multiple trades ranging from $266.520 to $267.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 20 | Common | Common Stock | 2026-02-24 | S | D | 6,671 | $268.04 | 4,706 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F7) The transaction was executed in multiple trades ranging from $267.520 to $268.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 21 | Common | Common Stock | 2026-02-24 | S | D | 3,963 | $268.97 | 743 | D Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F8) The transaction was executed in multiple trades ranging from $268.540 to $269.530. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F13) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 22 | Derivative | Stock Option (Right to Buy) | 2026-02-24 | M | D | 37,895 | $0.00 | 0 | D | $2.46 · — to 2026-11-09 | 37,895 Common Stock | (F24) The options vested ratably over a four-year period beginning on November 10, 2016. |